Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
2 hedge funds and large institutions have $820K invested in Global X China Biotech Innovation ETF in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
27% less capital invested
Capital invested by funds: $1.13M → $820K (-$310K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$592K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$892K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $557K | +$592K | +34,297 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $263K | -$892K | -51,675 | -76% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$20K | -1,205 | Closed |
|
CHB Hedge Fund Activity: Q1 2021 in Review
2 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q1 2021, worth a combined $820K — down 27% from $1.13M a quarter earlier.
Fund positioning in CHB was balanced in Q1 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $592K. The largest seller was Susquehanna International Group, cutting an estimated $892K.
- 2 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $820K of Global X China Biotech Innovation ETF stock for Q1 2021, down 27% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q1 2021 and 1 closed out, a net change of 0 holders.
- The largest Global X China Biotech Innovation ETF buyer in Q1 2021 was Jane Street, an estimated $592K added.
- The largest Global X China Biotech Innovation ETF seller in Q1 2021 was Susquehanna International Group, an estimated $892K sold.
Based on aggregated 13F filings for Q1 2021.